Recently, the Supreme People's Court rendered second-instance judgments on two cases represented by Unitalen Law Office: 1. The case of technical secret infringement dispute filed by Shanghai Cathay Biotech Inc. and Cathay (Jinxiang) Biomaterials Co., Ltd. (hereinafter referred to as "Cathay Biotech") against Shandong Hanlin Biotechnology Co., Ltd. (hereinafter referred to as "Shandong Hanlin") and its legal representative CAO XX, as well as former employees WANG XX and GE XX of Cathay Biotech [Case No.: (2022) Zui Gao Fa Zhi Min Zhong No. 445]; 2. The case of an invention patent infringement dispute filed by Cathay Biotech against Shandong Hanlin and Shandong Guiyuan Biotechnology Co., Ltd. (hereinafter referred to as "Shandong Guiyuan") [Case No.: (2023) Zui Gao Fa Zhi Min Zhong No. 3178]. Cathay Biotech received favorable second-instance judgments in both cases.

The Case (2022) Zui Gao Fa Zhi Min Zhong No. 445 is a civil infringement lawsuit initiated against the infringing entities and individuals involved in a prior criminal case related to trade secrets. In the second-instance judgment of this case, in addition to ordering the infringing party to immediately cease disclosing, using, or permitting others to use the identified trade secrets in question, including infringing acts such as leasing production lines to circumvent infringement, and confirming that Cathay Biotech is entitled to a general claim of RMB 28,874,473.02 against Shandong Hanlin, the court further ordered CAO XX and WANG XX to bear joint and several liability for the aforementioned debts, and GE XX to bear joint and several liability for RMB 8,662,341.90 of those debts.

In the Case (2023) Zui Gao Fa Zhi Min Zhong No. 3178, a dispute case over invention patent infringement, it was ruled that Shandong Guiyuan shall immediately cease using the patent method in question owned by Cathay Biotech, stop selling long carbon chain dicarboxylic acid products directly obtained by virtue of the patent method, compensate Cathay Biotech for economic losses of RMB 30 million, and Shandong Hanlin shall bear joint and several liability for compensation. In this case, given the malicious infringement committed by Shandong Hanlin and Shandong Guiyuan and the serious infringement circumstances arising therefrom, the courts in both instances applied punitive damages twice the amount of the compensatory damages.

The second-instance judgments in both cases have safeguarded Cathay Biotech's legitimate rights and interests, demonstrating the judiciary's robust protection of innovative achievements. The victories in two cases are attributable to unwavering trust in Cathay Biotech and its strong technical support, as well as the legal team's in-depth research, proactive evidence presentation, and precise grasp of the legal issues at play.